Tuesday, Aug 11, 2009
Hawaii Biotech has won a three-year, $2.9 million SBIR phase II grant from the National Institute of Allergy and Infectious Disease to continue development of a vaccine to protect healthy individuals from Tick-Borne Encephalitis, the company said in a press release.
TBE is most commonly recognized a...